Tat-haFGF14–154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1α/XBP1 Pathway

• Published in: Molecular therapy. Nucleic acids Vol. 7; no. C; pp. 439 - 452
• Main Authors: Meng, Tian, Cao, Qin, Lei, Peng, Bush, Ashley I., Xiang, Qi, Su, Zhijian, He, Xiang, Rogers, Jack T., Chiu, Ing-Ming, Zhang, Qihao, Huang, Yadong
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 16.06.2017; American Society of Gene & Cell Therapy; Elsevier
• Subjects: ADAM10; aFGF; Alzheimer’s disease; APP/PS1 mice; CREB; intranasal administration; Original; PI3K; Tat-PTD; XBP1; Aβ; XBP1; Tat-PTD; APP/PS1 mice; CREB; Alzheimer’s disease; PI3K; intranasal administration; aFGF; ADAM10
• ISSN: 2162-2531; 2162-2531
• DOI: 10.1016/j.omtn.2017.05.004

Acid fibroblast growth factor (aFGF) has shown neuroprotection in Alzheimer’s disease (AD) models in previous studies, yet its mechanism is still uncertain. Here we report that the efficacy of Tat-haFGF14–154 is markedly increased when loaded cationic liposomes for intranasal delivery are intranasal...